How much funding has eGenesis raised?

eGenesis has raised $316.0M in total funding, most recently a Series D round.

Who are eGenesis's investors?

eGenesis's investors include Lux Capital, Fresenius Medical Care, Biomatics Capital Partners, ARCH Venture Partners, Farallon Capital, Polaris Partners.

Where is eGenesis headquartered?

eGenesis is headquartered in Cambridge, Massachusetts, United States.

What industry is eGenesis in?

eGenesis operates in Biotech, Healthcare.

eGenesis

Restoring life after organ failure.

Cambridge, United States · Founded 2015 · $316.0M raised

Biotech

Healthcare

Headquarters: Cambridge, Massachusetts
Employees: 51–200
Founded: 2015
Business Model: B2B

Website: egenesisbio.com
Total Funding: $316.0M
Last Round: $191.0M Series DSep 2024
Rounds: 4

About

eGenesis is a biotechnology company developing human-compatible organs using multiplexed gene editing and genome engineering. Focused on kidney, liver, and heart transplants via xenotransplantation from genetically modified pigs to end organ shortages and waitlists. Achieved FDA IND clearance for Phase 1/2/3 kidney trials.

Summary

eGenesis is a Biotech company based in Cambridge, United States, founded in 2015. It has raised $316.0M in total across 4 rounds, most recently a $191.0M Series D round in Sep 2024. Investors include Lux Capital, Fresenius Medical Care and Biomatics Capital Partners.